BEIGENE LTD-ADR (ONC) Stock News

BeiGene Stock Meets 80-Plus RS Rating Benchmark

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

10 Health Care Stocks With Whale Alerts In Today's Session

Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?

Wall Street rebounds after Fed meeting with all major indices up, buoyed by earnings & dovish expectations. Probability for March cut at 41%, speculators increase bets for future cuts. Jobless claims up, manufacturing data beats expectations. S&P 500 & Nasdaq 100 gain 0.8%, regional banks suffer.

RBC Capital Thinks Oncolytics Biotech’s Stock is Going to Recover

A Wall Street analyst has provided a review for the Healthcare company yesterday, but retained the same rating on the stock. Analyst Douglas Miehm from RBC Capital rated Oncolytics Biotech (ONC – Research Report) a Buy, setting a C$10 price target. According to TipRanks.com, Miehm is ranked #4871 out of 5231 analysts. Read also: Tilray

Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech

In a new note to investors today, an analyst has provided a rating update for ...

The post Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech appeared first on Smarter Analyst.

Canaccord Genuity Issues a Buy Rating on Oncolytics Biotech

Today, an analyst has provided a rating update for the Healthcare company, Oncolytics Biotech (TSX: ...

The post Canaccord Genuity Issues a Buy Rating on Oncolytics Biotech appeared first on Smarter Analyst.

Canaccord Genuity Keeps a Buy Rating on Oncolytics Biotech

The Healthcare company, Oncolytics Biotech (TSX: ONC), has received a rating update from a Wall ...

The post Canaccord Genuity Keeps a Buy Rating on Oncolytics Biotech appeared first on Smarter Analyst.

Oncolytics Biotech Receives a Buy from Canaccord Genuity

The Healthcare company, Oncolytics Biotech (TSX: ONC), has received a rating update from a Wall Street analyst today. Analyst Neil Maruoka from Canaccord Genuity rated Oncolytics Biotech (TSX: ONC) a Buy, setting a C$2.50 price target. Maruoka said: “We believe this deal is a significant positive for Oncolytics, providing needed capital and drug development resources,

The post Oncolytics Biotech Receives a Buy from Canaccord Genuity appeared first on Analyst Ratings.

Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech

Oncolytics Biotech (TSX: ONC), the Healthcare company, has received a rating update from a Wall Street analyst yesterday. The company received a Buy rating from Canaccord Genuity’s analyst Neil Maruoka, with a C$1.50 price target. According to TipRanks.com, Maruoka is ranked 0 out of 5 stars with an average return of -3.1% and a 34.6%

The post Canaccord Genuity Assigns a Buy Rating on Oncolytics Biotech appeared first on Analyst Ratings.